Middle East And Asia Pacific Cell And Gene Therapy Market is Estimated To Witness High Growth Owing To Increasing Disease Burden

 
Middle East and Asia Pacific Cell And Gene Therapy Market

Market Overview:

The Middle East and Asia Pacific Cell And Gene Therapy Market Share comprises treatments that utilize cellular therapies and genetic modifications to repair damaged tissues and cells. These therapies deliver new cells, tissues or genes into patients to combat medical conditions. Cell therapies are derived from either autologous or allogenic sources while gene therapies involve the correction of genetic defects. The demand for these advanced treatment options is driven by their ability to potentially cure chronic diseases.

Market key trends:
The increasing prevalence of cancer and other life-threatening illnesses is a key factor augmenting the Middle East And Asia Pacific cell and gene therapy market growth. As per the World Health Organization, cancer cases in the Asia Pacific region are estimated to increase by 80% by 2030. Moreover, chronic diseases such as cardiovascular disorders are also on the rise in the Middle East region due to changing lifestyles. Cell and gene therapies present innovative solutions that can potentially provide long-lasting therapeutic effects by addressing the underlying causes at the cellular and genetic level. Increased healthcare investments by governments to make these novel treatment avenues more accessible to patients is fueling the market expansion.

Porter’s Analysis
Threat of new entrants: the Middle East and Asia Pacific cell and gene therapy market poses moderate threat of new entrants due to high level of investment required for R&D, manufacturing facilities and complexity of therapy development.
Bargaining power of buyers: buyers hold moderate bargaining power due to availability of limited product options and high treatment costs in this specialized therapy area.
Bargaining power of suppliers: suppliers have low to moderate bargaining power due to presence of a large number of raw material and service providers catering to this market
Threat of new substitutes: threat is low due to lack of effective substitutes for cell and gene therapies which are targeted therapies addressing specific medical conditions.
Competitive rivalry: the competition is high among existing players to develop new therapies and gain maximum market share.

SWOT Analysis
Strength: Availability of advanced healthcare infrastructure and high disposable incomes in the Asia Pacific region. Growing awareness about cell and gene therapies.
Weakness: High therapy costs making it unaffordable for majority. Stringent regulatory guidelines delaying product approvals.
Opportunity: Increasing prevalence of cancer, cardiovascular diseases and other genetic disorders driving demand. Favorable government initiatives supporting research.
Threats: Risk of therapy failure and side effects. Dependency on limited product pipelines of few large players.

Key Takeaways
The global Middle East And Asia Pacific Cell And Gene Therapy Market is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing prevalence of chronic diseases. The rising awareness about advanced therapies and favorable regulatory reforms supporting clinical trials will further support the market growth during the forecast period.

Regional analysis: Asia Pacific region dominates the market and is fastest growing region owing to presence of emerging economies like China and India experiencing high economic growth. High unmet medical needs and improving healthcare infrastructure in the region provide immense opportunities for cell and gene therapy providers.

Key players operating in the Middle East And Asia Pacific cell and gene therapy market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.

 

Read More:

https://www.dailyprbulletin.com/the-middle-east-and-asia-pacific-cell-and-gene-therapy-market/

Comments

Post a Comment

Popular posts from this blog

Precast Concrete Market Is Estimated To Witness High Growth Owing To Increasing Demand for Sustainable Construction Practices

Image
Precast Concrete Market Market Overview: The Precast Concrete Market is witnessing significant growth due to the increasing demand for sustainable construction practices. Precast concrete products are prefabricated in controlled factory conditions, offering several advantages such as improved quality control, reduced construction time, and increased durability. These products are widely used in residential, commercial, and infrastructure projects due to their ability to enhance construction efficiency and productivity. With the growing need for energy-efficient and environmentally friendly buildings, the demand for precast concrete products is expected to rise. Market Key Trends: One key trend in the Precast Concrete Market is the adoption of advanced technology in manufacturing processes. The use of computer-aided design (CAD) and building information modeling (BIM) is enabling manufacturers to produce complex and customized precast concrete products with high precision. Additional
Read more

Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market Growth driven by increased adoption of targeted therapies

Image
Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market Market Overview: Relapsed Or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) is an aggressive fast-growing type of non-Hodgkin's lymphoma (NHL) cancer that generally affects immune system cells called B cells. DLBCL can occur at any age but is most common in older adults. Novel targeted therapies like chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies and antibody-drug conjugates are revolutionizing the treatment of R/R DLBCL. These advanced therapies are offering new hope to patients by increasing survival rates. Market key trends: One of the key trends in the R/R DLBCL market is the increasing adoption of CAR T-cell therapies. CAR T-cell therapy is an innovative new approach to treating R/R DLBCL through the use of genetically engineered T-cells. Drugs like Kymriah and Yescarta have proven highly effective in treating certain patients with relapsed or refractory forms of large B-cell lymphoma.
Read more

The global Biopharmaceuticals Market connected with therapeutic biologics

Image
Biopharmaceuticals Market Market Overview: The biopharmaceuticals market comprises medicines produced using biotechnology methods like genetic engineering and includes vaccines, blood components, recombinant therapeutic proteins/antibodies, and monoclonal antibodies. Biopharmaceuticals are often used for treating serious medical conditions like cancer, autoimmune diseases, and other chronic disorders. These drugs provide targeted treatment options and have lesser side effects than traditional small-molecule drugs. The market is witnessing high demand due to increasing prevalence of chronic diseases and growing geriatric population globally. Market key trends: One of the key trends gaining traction in The Biopharmaceuticals Market Demand is the increasing adoption of biosimilars. Biosimilars are quasi-generic versions of original biologics and provide more affordable treatment options when the patents of biologics expire. Regulatory agencies in various regions are also approving bios
Read more